This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycofenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical sibling. Bone Marrow Transplant 2005; 35: 1089–1093.
Niederwieser D, Maris M, Schizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total irradiation (TBI) and fludarabin followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycofenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological disease. Blood 2003; 101: 1620–1629.
Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycofenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499–509.
Pohlreich D, Vitek A, Valkova V, Markova M, Maalouf J, Kouba M et al. Cyclosporine-methotrexate versus cyclosporine-mycophenolate in the prevention of GvHD in stem cell transplantation using myeloablative regimens. Bone Marrow Transplant 2005; 35 (Suppl 2): 149.
Bolwell BJ, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporin+short course methotrexate to cyclosporine+mycophenolate for GVHD prophylaxis in ablative allogeneic BMT. Bone Marrow Transplant 2004; 34: 621–625.
Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host-disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922–2924.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pohlreich, D., Vitek, A., Maalouf, J. et al. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens. Bone Marrow Transplant 37, 235–236 (2006). https://doi.org/10.1038/sj.bmt.1705227
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705227
This article is cited by
-
Comparative analysis of graft-versus-host disease prophylaxis with tacrolimus in combination with methylprednisolone or methotrexate after umbilical cord blood transplantation
International Journal of Hematology (2020)
-
Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation
Annals of Hematology (2019)
-
Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation
International Journal of Hematology (2017)